Diaxonhit Signs a Research Service Agreement with Boehringer Ingelheim
Diaxonhit enters into a research service agreement with Boehringer Ingelheim for the discovery and characterization of novel splice variants that have the potential to be therapeutic targets for oncology. Through the agreement Boehringer Ingelheim secures an option to acquire the rights to research, develop and commercialize, any targets identified using Diaxonhit’s patented SpliceArray™ discovery platform, with the aim of adding further to its comprehensive research programme to develop cancer drugs.
“This agreement with Boehringer Ingelheim demonstrates the continued interest in and effectiveness of our SpliceArrayTM discovery platform, and the expertise we have efficiently developed to exploit our comprehensive transcriptomic data for new target discovery ” said Loïc Maurel M.D., President of Diaxonhit’s Management Board.
Financial terms were not disclosed.
Most read news
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.